论文部分内容阅读
氨氯地平是新型二氢吡啶类钙通道阻滞剂。本文报道应用氨氯地平治疗６０例冠心病高血压患者的结果。第１组单纯口服氨氯地平，第２组口服氨氯地平加上生物反馈治疗，疗程均为８周。治疗结果表明，第１与第２组患者１４种症状的有效率分别为８４．１２％与９４．５％。１４种日常生活能力以及卡氏心功能测定均有明显的改善，但第２组的效果更好（Ｐ＜０．０５）。氨氯地平的降压作用明显，舒张压的下降略逊于收缩压，加用生物反馈治疗后，有效率从８６．６２％增至９３．３４％。在第１与第２组中，心绞痛的发作分别减少了５２．６４％与７０％。
Amlodipine is a novel dihydropyridine calcium channel blocker. This article reports the use of amlodipine in the treatment of 60 patients with coronary heart disease in patients with hypertension results. The first group of simple oral amlodipine, the second group of oral amlodipine plus biofeedback treatment, treatment were 8 weeks. Treatment results showed that the first group and the second group of 14 symptoms were 84.12% and 94.5%, respectively. 14 kinds of daily living ability and cardiocardiography were significantly improved, but the second group is better (P <0.05). Amlodipine obvious antihypertensive effect, diastolic blood pressure decreased slightly less than the systolic blood pressure, plus biofeedback treatment, the effective rate increased from 86.62% to 93.34%. In Groups 1 and 2, angina attacks decreased by 52.64% and 70%, respectively.